A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
(Q82758717)
scientific article published on 02 February 2010
scientific article published on 02 February 2010
Language:
other details
| description | scientific article published on 02 February 2010 |
External Links
| (P356) |
10.1007/S10637-010-9392-8
|
| (P698) |
20127139
|
| (P6179) |
1033795025
|